STRYKER CORP (SYK) Form 8-K — Oct 29, 2026
Stryker reported Q3 2026 net sales of $6.5 billion, up 7.7% on a reported and organic basis, led by 9.2% growth in MedSurg and Neurotechnology and 5.7% in Orthopaedics. Adjusted EPS rose 10.3% to $3.52, but reported EPS fell 11.7% to $1.96, weighed down by a $293 million goodwill impairment plus structural optimization and Spinal Implants exit-related charges. CEO Kevin Lobo said performance 'did fall short of our expectations' despite strong fundamentals, and Stryker updated full-year 2026 guidance to 6.5-7.0% organic growth and adjusted EPS of $14.80-$14.90.
Key figures
- Eps
- 1.96
- Revenue
- 6520000000
- Guidance
- Full year 2026 organic net sales growth of 6.5% to 7.0%; adjusted EPS of $14.80 to $14.90
- Net Income
- 753000000
- Total Debt
- 14176000000
- Revenue Yoy
- 7.7%
- Total Assets
- 47247000000
- Cash Position
- 3271000000
- Q3 buybacks
- $1.0 billion
- Adjusted eps
- $3.52 (+10.3%)
- Medsurg growth
- 9.2%
- Organic growth
- 7.7%
- Buyback increase
- $3.0 billion
- Goodwill impairment
- $293 million
- Orthopaedics growth
- 5.7%
- Adjusted net earnings
- $1.4 billion (+10.1%)
- Adjusted operating margin
- 26.2% (+60 bps)
- Reported operating margin
- 15.9%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.